KURA241220P7500
- 0.10
- -0.05-33.33%
Kura Oncology Newsroom
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $18 to $34
B of A Securities Maintains Buy on Kura Oncology, Lowers Price Target to $29
Kura Oncology Analyst Ratings
Kura Oncology's Strategic Developments and Partnership With Kyowa Kirin Justify Buy Rating, Despite Initial Stock Dip
Barclays Reaffirms Their Buy Rating on Kura Oncology (KURA)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Analysts Supportive of Kura/Kirin Deal Despite Major Selloff in Shares
Kura Oncology Shares Are Trading Lower. The Company Announced It Entered Into a Global Strategic Collaboration With Kyowa Kirin to Develop and Commercialize Ziftomenib.
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
Kura Oncology Tumbles as Kyowa Collaboration Seen Hitting M&A Prospects
Kura Oncology Price Target Cut to $28.00/Share From $32.00 by Jefferies
Kura Oncology Is Maintained at Buy by Jefferies
Kura Oncology's Commercialization Deal Isn't What Investors Wanted -- Market Talk
Cantor Fitzgerald Reiterates Overweight on Kura Oncology
Kura Oncology Price Target Lowered to $34 From $37 at Wedbush
Kura Oncology (KURA) Receives a Buy From TD Cowen
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $30
Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Strategic Partnership With Kyowa Kirin Strengthens Kura Oncology's Financial and Commercial Position
Wedbush Lowers Price Target on Kura Oncology to $34 From $37, Keeps Outperform Rating